

05-26-04

1645

0330

Express Mail Label No.: EV392162566US

Date of Deposit: May 24, 2004

Attorney Docket No. 15966-575B (Cura-75B)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Prayaga et al.
SERIAL NUMBER: 09/679,740 EXAMINER: Not Yet Assigned
FILING DATE: October 5, 2000 ART UNIT: 1645
FOR: Endozepine-Like Polypeptides and Polynucleotides Encoding Same

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:

1. Copy of Response to Notice to Comply with Sequence Listing filed September 14, 2001 including:
 - a. Copy of Transmittal Letter (1 pg.)
 - b. Preliminary Amendment and Notice to Comply with Sequence Listing Requirements (2 pgs);
 - c. Notice to Comply Sequence Listing Requirements (2 pgs.);
 - d. Substitute Specification (138 pgs.);
 - e. Marked-Up Version of Specification Showing Changes (140 pgs.);
 - f. Statement in Support of Substitute Specification (1 pg.);
 - g. Sequence Listing, paper copy (90 pgs.);
 - h. Sequence Listing Computer Readable Form (1 disk);
 - i. Statement in Support of Computer Readable Form Submission 37 C.F.R. § 1.821 (f) (1 pg.);
 - j. Copy of date-stamped postcard and Express mail receipt (1pg.);
2. Status Inquiry (1 pg.); and
3. Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311, Ref. No. 15966-575B. A duplicate copy of this transmittal letter is enclosed herewith.

Dated: May 24, 2004

Respectfully submitted,

Ivor R. Elfi
Ivor R. Elfi, Reg. No. 39,529
Attorney for Applicants
c/o MINTZ, LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Express Mail Label No.:EV392162566US

Date of Deposit: May 24, 2004

ATTORNEY DOCKET NO.: 15966-575B (CURA-75B)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Prayaga *et al*
SERIAL NUMBER: 09/679,740 EXAMINER: Not Yet Assigned
FILING DATE: October 5, 2000 ART UNIT: 1645
TITLE: ENDOZEPINE-LIKE POLYPEPTIDES AND POLYNUCLEOTIDES
ENCODING SAME

Commissioner for Patents
P.O. Box 1450
Washington, D.C. 22313-1450


STATUS INQUIRY

A Response to a Notice To Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, mailed on July 17, 2001, was filed for the above-referenced application on September 14, 2001. Copies of the Notice and Response are included. Applicants respectfully request to be informed of the current status of the application.

No fees are believed due in connection with this communication. However, the Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 15966-575B (Cura-75B). A duplicate copy of this communication is enclosed.

Respectfully submitted,

Dated: May 24, 2004

For 
Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
c/o MINTZ, LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Date of Deposit: September 14, 2001



Attorney Docket Number: 15966-575B (Cura-75B)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Prayaga, *et al.*
SERIAL NUMBER: 09/679,740 EXAMINER: Not Yet Assigned
FILING DATE: October 5, 2000 ART UNIT: 1645
FOR: ENDOZEPINE-LIKE POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING
SAME

BOX SEQUENCE LISTING

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:

1. Preliminary Amendment and Notice to Comply with Sequence Listing Requirements (2 pgs.);
2. Notice to Comply with Sequence Listing Requirements (1 pg.);
3. Substitute Specification (137 pgs);
4. Marked-Up Version of Specification Showing Changes (139 pgs);
5. Statement in Support of Substitute Specification (1 pg.);
6. Sequence Listing, paper copy (90 pgs);
7. Sequence Listing Computer Readable Form (1 disk);
8. Statement in Support of Computer Readable Form Submission under 37 C.F.R. § 1.821(f) (1 page); and,
9. Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.


The Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311, Ref. No.15966-575B. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529
Cynthia A. Kozakiewicz, Reg. No. 42,764
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: September 14, 2001
TRA 1565066v1

EL8622126379US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Prayaga, *et al*
SERIAL NUMBER: 09/679,740 EXAMINER: Not Yet Assigned
FILING DATE: October 5, 2000 ART UNIT: 1645
FOR: ENDOZEPINE-LIKE POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME

BOX SEQUENCE LISTING
Assistant Commissioner for Patents
Washington, D.C. 20231

STATEMENT IN SUPPORT OF SUBSTITUTE SPECIFICATION

Pursuant to 37 CFR 1.125(b)(1), I hereby state that the content of the substitute specification enclosed herewith and the specification filed on October 5, 200 are the same. The amendments to the specification introduce sequence identifier numbers ("SEQ ID NO:") that correspond to polynucleotide and polypeptide sequences disclosed in the specification and Tables summarizing the assignment of the sequence identifiers. Thus, this submission includes no new matter.

Applicants believe that no fee is required for the filing of the present submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to Deposit Account No. 50-0311, Ref. No. 15966-575B (CURA75B).

Respectfully submitted,

A handwritten signature in black ink, appearing to be "Ivor R. Elrifi", written over a horizontal line.

Ivor R. Elrifi, Reg. No. 39,529
Cynthia A. Kozakiewicz, Reg. No. 42,764
Attorney for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: September 14, 2001



POST OFFICE TO ADDRESSEE



EL 862126379 US

ORIGIN (POSTAL USE ONLY)

Pr. ZIP Code 0 205	Day of Delivery <input type="checkbox"/> Next <input type="checkbox"/> Second	Flat Rate Envelope <input type="checkbox"/>
Date In 9 14 01	<input type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	Postage \$ 24.85
Time In <input type="checkbox"/> AM <input checked="" type="checkbox"/> PM	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Return Receipt Fee
Weight 4 lbs. 2 ozs.	Int'l Alpha Country Code	COD Fee Insurance Fee
No Delivery <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday	Acceptance Clerk Initials S/B	Total Postage & Fees \$ 24.85

SEE REVERSE SIDE FOR
SERVICE GUARANTEE AND LIMIT
ON INSURANCE COVERAGE

☐ **WAIVER OF SIGNATURE** (Domestic Only): Additional merchandise (merchandise) void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and I authorize that delivery employee's signature constitutes valid proof of delivery.

NO DELIVERY ☐ Weekend ☐ Holiday

Customer Signature

CUSTOMER USE ONLY**METHOD OF PAYMENT:**

Express Mail Corporate Acct. No.

Federal Agency Acct. No. or
Postal Service Acct. No.**FROM: (PLEASE PRINT)**

PHONE ()

MINI 2 LEVIN CORN FERRIS
GLOVSY & POPPO PC
1 FINANCIAL CTR
BOSTON

MA 02111-2021

II/CAK 15966-575B (Cura 75B)

TO: (PLEASE PRINT)

PHONE ()

Box Sequence Listing
Assistant Commissioner for Patents
Washington, DC 202312

FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com



Customer Copy
Label 11-F August 2000
Label 11-F August 2000

Serial No. 09/679,740 File No. 15966-575B By: IRE/CAK
Title: Endozepine-Like Polypeptides and Polynucleotides...
Application of Prayaga, et al Date: October 5, 2000

The U.S. PTO Mail Room acknowledges receipt of the following on the date stamped hereon:

- | | |
|---|---|
| <input type="checkbox"/> Req. for CPA under 37 CFR 1.53(d) | <input type="checkbox"/> Provisional Application Cover Sheet |
| <input type="checkbox"/> Change of Attorney's Address | <input type="checkbox"/> Inf. Disc. Statement, PTO Form 1449 |
| <input type="checkbox"/> New Power of Attorney | <input type="checkbox"/> References Cited |
| <input type="checkbox"/> Patent Application | <input checked="" type="checkbox"/> Copy of Notice to Inventors, Comply (1) |
| <input type="checkbox"/> Non-provisional <input type="checkbox"/> Provisional | <input checked="" type="checkbox"/> Amendment/Response (2 pgs) |
| Incl. _____ pages, (_____ pgs) Specification | <input type="checkbox"/> Petition for Ext. of Time (x2) |
| (_____ pgs) Abstract, (_____ pgs) Claims (_____ # claims) | <input type="checkbox"/> Issue Fee Transmittal |
| <input type="checkbox"/> Design Patent Application | <input type="checkbox"/> Letter to Official Draftsperson |
| <input type="checkbox"/> Declaration(s) | <input type="checkbox"/> Notice of Appeal |
| <input type="checkbox"/> Drawings _____ sheet(s) (FIGS. _____) | <input type="checkbox"/> Brief (x3) |
| <input type="checkbox"/> Formal <input type="checkbox"/> Informal | <input type="checkbox"/> Check for \$ _____ Check # _____ |
| <input type="checkbox"/> Verified Statement claiming small entity status | <input checked="" type="checkbox"/> Transmittal Letter (x2) |
| <input type="checkbox"/> Assignment and Cover Sheet | <input type="checkbox"/> Cert. of Mailing under 37 CFR 1.8(a) |
| | <input checked="" type="checkbox"/> Express Mail Label No. <u>EL862126379US</u> |

☐ Other Sequence Listing (90 pgs) (1 disk); Substitute Spec.
(137 pgs) Redlined Specification (139 pgs); Statement
in Support of Substitute Spec. (1 pg); Statement in
Support of Computer Readable Form (1 pg)

DATE MAILED September 14, 2001

BEST AVAILABLE COPY

(1) Other Sequence Listing (90 pgs) (1 disk); Substitute Spec.